ABOUT 17th_ELSF
​> AGENDA​
​> REGISTRATION​
​> ATTENDEES​
​> INVESTORS​
​> PRESENTERS​
​> EXHIBITORS​
​> SPONSORS​
​> SUPPORTERS​
​> NETWORKING​
> VENUE​
> ACCOMMODATION​

> ABOUT LAST YEAR​

We are pleased to announce that the 17th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 28th - 29th February 2024 back at the Hilton Zurich Airport Hotel. The event will be part of the Sachs Spring Life Sciences Week, which will also incorporate the 5th Annual European HealthTech CEO Forum.  

The success and longevity of the forum is built on the goodwill and repeat attendance of major corporate and financial investors, and pharma licensing executives and advisors, who are seeking to network with biotechs. The programme and presentations allow all to keep up with the latest industry developments and strategize for 2024. The physical programme will consist of the usual panels and keynotes, which will be available on demand from the 6th of March. Additionally, there will be pre-arranged in-person meetings, live and on demand company showcases and a reception. During the online week, virtual meetings will be available through the audio/video online meeting system.

The main programme for the 17th Annual ELSF is spread throughout 2 days (28th - 29th of February) and will feature more than 12 hours of high-level keynotes and panel discussions. In addition, there will be a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities. This will include a limited number of live presentations taking place in dedicated presentation tracks, alongside virtual company showcases, which will be available on demand during the virtual week. We anticipate 400+ delegates will register for the forum from all Life Sciences sectors, with the target audience being corporate and financial investors/partners, banks and advisors with part of the audience participating virtually.

The In-Person meetings will be taking place on the 28th - 29th of February, while virtual meetings will take place on the 6th - 8th of March. For the virtual meetings, the system will allow you to have a secure audio/video call, as well as the option to present slides using a screen share function and we will have a dedicated room for in-person meetings. We expect 1800+ meetings completed during SSLSW. The conference will be held in the Central European Time Zone and the programme will consist of:

Day 1 (Wednesday, 28th of February) 

• Industry Roundtable: Charting the Course for 2024
• Investment Outlook for VC & PE Panel: Focusing on Current Portfolio & Additions
• Cardiomet & Obesity Panel: Meeting the Huge Unmet Need
• Rare & Orphan Therapies Panel: Gene Therapy & Other Modalities
• Investing in NextGen ADC'S Panel
• Neuro Advances Panel: Highlighting the Main Opportunities

Day 2 (Thursday, 29th of February) 

• Greater China Biopharma Panel: Potential Role in the European Life Science Industry
• Pharma Dealmakers Panel: Viewing the Challenges from Both Sides
• Oncology BD&L Panel: Keeping Pace with Market Needs
• Cancer Progress Panel: Advances in Therapeutics
• Early-Stage Investment Panel: Addressing the Funding Need
• Rising Stars: Global Biotech Seed Session

In-Person Meetings – 28th - 29th of February 
Virtual Meetings via Online Meeting System – 6th - 8th of March  
Networking Reception – 28th of February 
On-Demand Content – from 6th of March

Confirmed Keynote Speakers Include:

• "Opportunities for European Life Sciences & Healthcare Companies in the Hong Kong Capital Markets" by Chris Roberts, Head of EMEA Issuer Services, Hong Kong Exchanges and Clearing Limited
• “Overcoming Obesity—The Discovery of Multi-Receptor Drugs” by  Matthias Tschöp , Chief Executive Officer & Chief Scientific Officer,  Helmholtz Munich
  
• "AI in the Life Sciences: Hallucinations or Innovations?" by Liesbeth Ceelen, CEO, Biolizard SA

Confirmed Chairs & Speakers Include:

• Alessandra Polara, Senior Director, Global BD, F. Hoffmann-La Roche AG
• Allan Marchington, Managing Director, Head of Life Sciences, Intermediate Capital Group PLC
• Andreas Jurgeit, Partner, Gimv
• Andreas Pahl, CEO, Heidelberg Pharma AG
• Andreas Wallnoefer, Partner, Jeito Capital
• Anna Lisa Picciolo-Lehrke, Head Business Development Neurology, UCB Pharma
• Antoine Boulanger, Principal, Forbion
• Apollon Papadimitriou, CEO, iOmx Therapeutics AG
• Aram Mangasarian, CEO, TME Pharma
• Astrid Maria Dahl, COO & Head of Europe, Innovent Biologics
• Asun Monfort, Investment Advisor, HBM Partners AG
• Bauke Anninga, Investment Director, M Ventures
• Benjamin Thomas, Senior Vice President - Operations, Oxford BioTherapeutics Ltd.
• Birgit Steckel-Hamann, Sr. Director Diabetes External Innovation & Head of Public Private Partnerships Europe, Eli Lilly and Company
• Carlos Buesa, Founder & CEO, Oryzon Genomics, S.A.
• Chris Roberts, Head of EMEA Issuer Services, Hong Kong Exchanges and Clearing Limited
• ​Christian Thomsen, Global Head, CNS BD&L, Boehringer Ingelheim International GmbH
• Dani Bach, Partner, +ND Capital
• Daniel Parera, Partner, Kurma Partners
• David Colpman, Director, Alpina Life Science Advisors
• Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA
• Donald Xu, Managing Partner, Lynx Financial Hong Kong Ltd.
• Dragan Grabulovski, Acting CEO, Araris Biotech AG
• Edouard Caram, Sr Director, Global Partnership Rare Diseases & Neurosciences, Ipsen
• Emin Fadillioglu, CEO, Eczacibasi Pharmaceutical and Industrial Investment Co.
• Eric Halioua, President & CEO, PDC*line Pharma SA
• Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG
• Evonne Sepsis, Managing Director, ESC Advisors
• Francois Ravenelle, Founder & CEO, Inversago Pharma Inc.
• François Thomas, Operating Partner, Quadrille Capital
• Georgia Frost, Senior Associate, Dementia Discovery Fund - SV Health Investors LLP
• Göran Forsberg, CEO, Cantargia AB
• Helen Chen, Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner, L.E.K. Consulting
• Jesus Baena, BD&L Transactions Director, Novartis AG
• Joachim Vogt, Director Search & Evaluation International, AbbVie, Inc.
• Jonathan Tobin, Partner, Brandon Capital
• Josua Jordi, Co-Founder & CEO, EraCal Therapeutics Ltd.
• Katya Smirnyagina, Senior Partner, Oxford Science Enterprises
• Kelly Curtin, Managing Director, Stifel
• Khatereh Ahmadi, Head of Search & Evaluation Business Development, Europe & Middle East, MSD
• Klaus Breiner, Managing Partner, Pureos Bioventures
• Klaus Dugi, CEO, Vandria SA
• Konstantin Petropoulos, CBO & Managing Director, Secarna Pharmaceuticals GmbH & Co. KG
• Lubor Gaal, CFO & Head of BD & Alliance Management, Circio Holding ASA
• Lynn Durham, Founder & CEO, STALICLA SA
• Marc Ditmarsch, Chief Development Officer, NewAmsterdam Pharma
• Marc Robillard, CEO, Tagworks Pharmaceuticals BV
• Marie Leblanc, Executive Director, Global Head of Account Management, Cell & Gene Technologies, Lonza AG
• Mark Rayner, Managing Partner, GOLDTRACK Ventures GmbH
• Michael Altorfer, CEO, Swiss Biotech Association
• Michael Hübner, Director Early Innovation Partnering, Johnson & Johnson Innovation LLC
• Nathalie ter Wengel, European Lead, Worldwide Business Development, Pfizer, Inc.
• Naveed Siddiqi, Senior Partner, Novo Holdings A/S
• Nigel Sheail, Venture Partner, Versant Ventures
• Olav Zilian, Senior Equity Analyst - Healthcare, Pictet & Cie SA
• Paul Hermant, Partner, Bird & Bird LLP
• Peter Braun, CEO, TargImmune Therapeutics AG
• Philip Larsen, CEO, SixPeaks Bio
• Rianne Ellenbroek, Principal, BioGeneration Ventures
• Richard Ward, Executive Director, Search & Evaluation, AstraZeneca
• Sandra von Meier, Head Business Development & Licensing, Debiopharm International SA
• Sarah Holland, President of Swiss Healthcare Licensing Group & CBO, Cureteq AG
• Sascha Berger, Partner, TVM Capital Life Science
• Simon Chandler, CEO, Rinri Therapeutics Ltd.
• Søren Møller, Managing Partner, Novo Holdings A/S
• Stacy Lindborg, Co-CEO, Brainstorm Cell Therapeutics, Inc.
• Stefano Portolano, CEO, Azafaros Switzerland AG
• Stephan Lensky, COO & CBO, EpimAb Biotherapeutics
• Stephanie Léouzon, Managing Director, Stifel
• Stephen Doyle, Chief Business Officer, Aslan Pharmaceuticals
• Stephen Myatt, CEO, Macomics Ltd.
• Susan Hill, CEO, Mestag Therapeutics Ltd.
• Tamas Schweighoffer, Co-Founding Partner, Forty51 Ventures AG
• Tom Shepherd, CEO, Captor Therapeutics S.A.
• Ulrich Wendt, Global Head Business Development Immunology & Inflammation, Sanofi
• Victoria English, Co-Founder & Editor of Evernow Publishing Ltd, publisher, MedNous
• More TBA...

To view the full list of speakers in 2023, please click here.

PARTICIPATION OPTIONS:

Complimentary passes are provided for qualified institutional (buy/sell-side), private equity and venture investors. The number of passes is limited, and priority is given to regular participants, however the organiser has the discretion to reject registrations. Other participants may consider purchasing access, which includes in-person or virtual participation, with different options to showcase your company. 

NETWORKING OPPORTUNITIES:

The Online Meeting System will open on the 13th of February for uploading profiles and sending meeting invites. The in-person meetings will be taking place on the 28th - 29th of February, while virtual meetings will take place on the 6th - 8th of March. For the virtual meetings, the system will allow you to have a secure audio/video call, as well as the option to present slides using a screen share function and we will have a dedicated room for in-person meetings. 

PRESENTING OPPORTUNITIES:

Presentations are a popular and useful way to gain additional exposure with potential investors and pharma partners, which make up over half the audience. We are pleased to announce that once again we will have 20-minute and 10-minute presentations taking place in-person at the dedicated presenting tracks. Here you will be able to showcase your company in front of investors attending the physical event. The recording will be added to your company’s profile later, which will be available on demand for registered participants until the event portal closes. Start-up companies, which are looking for seed financing can apply for a Rising Stars – Seed Companies Session. 

For those who are not able to present in-person, but are still interested to showcase their company, there is an option to purchase either a 20-minute or 10-minute presentation, which will be pre-recorded in advance and available to all registered attendees on the event’s portal. Start-up companies may also purchase a 5-minute pre-recorded showcase instead.

The Sachs Team can assist with the pre-recording of the presentation, or you can upload a video you already have. Interested viewers will be able to message or request a meeting with you using the Online Meeting System.

Confirmed Presenters Include:

EXHIBITING OPPORTUNITIES: 

Make connections, engage in conversation, and exchange knowledge with key decision-makers eager to learn how your company can help them meet their goals and achieve their mission. Exhibiting at Sachs Spring Life Sciences Week is an effective way to gain leads, introduce new products and services, expand sales, and build relationships. 

If you are attending the physical event, we have a limited number of tabletop exhibitions available at the venue, restricted to three companies. These exhibitions will be located in the 'Zurich A&B' room, where the registration, breaks, and the highest attendee traffic are concentrated.

For those who are not able to join the event or exhibit in-person, you could choose virtual exhibition package, which includes a dedicated virtual page, where we can upload your branded company’s profile and list ways to reach you, share video or images about services you provide and have files ready for download if you wish to share any additional information with potential clients.

If interested in learning more about exhibition options, please fill in the registration form.

SPONSORING OPPORTUNITIES: 

There are a limited number of sponsorship opportunities for the forum, which include speaking, advertising, and branding options. Sponsors typically include investment banks and funds, large pharma, technology companies and service providers, including Stock Exchanges, IR companies, CROs, international lawyers and consulting companies. Tailored packages are available upon request. You can view the latest event’s sponsors here.

To learn more about presenting, exhibition or sponsorship opportunities, please fill in registration form or contact us at [email protected] or by phone + 44 (0)203 463 4890.

Silver Sponsor:

---

Bronze Sponsors:

---

Contributing Sponsor:

---

Silver Sponsor in 2023:

---

Bronze Sponsors in 2023:

---

Supporters:

---

Participating Pharmas in 2023:

---

Financial, Advisory & Investors Attending:

+ND Capital
AAA Family Office
AdBio Partners
AFK & Partners Asset Management LLC
Aglaia Oncology Funds
Aliath Bioventures
Amplitude Ventures
ARVE Capital GmbH
Bergmann zur Hausen & Cie. GmbH
BioMedPartners AG
BioMedVC AG
Bioqube Ventures
BlackRock
bmp Ventures AG
BOHE Angel Fund
Boostrap Europe
Bpifrance
Brandon Capital
Breslin AG
Business Angels Switzerland
CARMA FUND Management GmbH
Cathay Health
CEBINA Bridge Capital
Convergence Partners
DeBere Capital Partners
Debiopharm International S.A.
Delin Ventures Ltd.
Dementia Discovery Fund - SV Health Investors LLP
Digital Networks Plc. S.r.l.
ESC Advisors
Evoleen
Forbion
Forty51 Ventures
Forty51 Ventures AG
Fraser Finance
FutuRx
GIBF
Gimv
Global Life Science Ventures GmbH
H Tree Capital
Hadean Ventures
HBM Partners AG
High-Tech Gründerfonds Management GmbH
Indaco Bio Fund
Innovestor Life Science Ltd.
Intermediate Capital Group PLC
IPF Partners
Jeito Capital
Johnston Associates, Inc.
JP Morgan
Kinled Holding Limited
KIZOO Technology Capital GmbH
Kurma Partners
Landmark BioVentures AG
LifeLink Ventures
Longliv Ventures
LSA Ventures
LSV Capital Partners
M Ventures
M2Care
Mid Atlantic Bio Angels
Novartis Venture Fund
Novo Holdings A/S
NxR Biotechnologies GmbH
Oxford Science Enterprises
Panakès Partners SGR SpA
Pictet & Cie SA
Prevail Partners LLC
Private Equity Investor
Pureos Bioventures
Quadrille Capital
Redalpine Venture Partners AG
Rosetta Capital
Schroders Capital
Second Thought
Seroba Life Sciences
SPRIM Global Investments
Staatz Business Development & Strategy
Stifel
Strategic Transactions Advisory AG
Sunstone Life Science Ventures
Taiho Ventures
TruVenturo GmbH
TVM Capital Life Science
UCB Pharma
Versant Ventures
Vesalius Biocapital Partners Sàrl
VI Partners AG
Viopas Venture Consulting
Vogel BioC
XGEN Venture SGR S.p.A.
Ysios Capital
Ysios Capital Partners S.G.E.I.C., S.A.

To View All - Click Here